

# Yu-Shan Huang

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6724993/publications.pdf>

Version: 2024-02-01

40  
papers

621  
citations

623699

14  
h-index

677123

22  
g-index

40  
all docs

40  
docs citations

40  
times ranked

920  
citing authors

#	ARTICLE	IF	CITATIONS
1	Safety and immunogenicity of a Recombinant Stabilized Prefusion SARS-CoV-2 Spike Protein Vaccine (MVC COV1901) Adjuvanted with CpG 1018 and Aluminum Hydroxide in healthy adults: A Phase 1, dose-escalation study. <i>EClinicalMedicine</i> , 2021, 38, 100989.	7.1	56
2	Comparing visual inspection, aerobic colony counts, and adenosine triphosphate bioluminescence assay for evaluating surface cleanliness at a medical center. <i>American Journal of Infection Control</i> , 2015, 43, 882-886.	2.3	53
3	Treatment of <i>Pneumocystis jirovecii</i> pneumonia in HIV-infected patients: a review. <i>Expert Review of Anti-Infective Therapy</i> , 2017, 15, 873-892.	4.4	38
4	Renin-Angiotensin-Aldosterone System Inhibitors and Risks of Severe Acute Respiratory Syndrome Coronavirus 2 Infection. <i>Hypertension</i> , 2020, 76, 1563-1571.	2.7	36
5	Trends and outcomes of late initiation of combination antiretroviral therapy driven by late presentation among HIV-positive Taiwanese patients in the era of treatment scale-up. <i>PLoS ONE</i> , 2017, 12, e0179870.	2.5	31
6	Short-term outcomes of rapid initiation of antiretroviral therapy among HIV-positive patients: real-world experience from a single-centre retrospective cohort in Taiwan. <i>BMJ Open</i> , 2019, 9, e033246.	1.9	25
7	Prevalence of and risk factor for community-onset third-generation cephalosporin-resistant <i>Escherichia coli</i> bacteremia at a medical center in Taiwan. <i>BMC Infectious Diseases</i> , 2019, 19, 245.	2.9	23
8	Less Severe but Prolonged Course of Acute Hepatitis A in Human Immunodeficiency Virus (HIV)-Infected Patients Compared With HIV-Uninfected Patients During an Outbreak: A Multicenter Observational Study. <i>Clinical Infectious Diseases</i> , 2018, 67, 1595-1602.	5.8	21
9	Echinocandins as alternative treatment for HIV-infected patients with <i>Pneumocystis pneumonia</i> . <i>Aids</i> , 2019, 33, 1345-1351.	2.2	20
10	Effectiveness of switching from protease inhibitors to dolutegravir in combination with nucleoside reverse transcriptase inhibitors as maintenance antiretroviral therapy among HIV-positive patients. <i>International Journal of Antimicrobial Agents</i> , 2019, 54, 35-42.	2.5	19
11	Colonization With Multidrug-Resistant Organisms Among Healthy Adults in the Community Setting: Prevalence, Risk Factors, and Composition of Gut Microbiome. <i>Frontiers in Microbiology</i> , 2020, 11, 1402.	3.5	19
12	Long-term virological and serologic responses of chronic hepatitis B virus infection to tenofovir disoproxil fumarate-containing regimens in patients with HIV and hepatitis B coinfection. <i>Hepatology International</i> , 2019, 13, 431-439.	4.2	18
13	Virological Response to Tenofovir Disoproxil Fumarate in HIV-Positive Patients with Lamivudine-Resistant Hepatitis B Virus Coinfection in an Area Hyperendemic for Hepatitis B Virus Infection. <i>PLoS ONE</i> , 2016, 11, e0169228.	2.5	17
14	Increasing New Delhi metallo- $\beta$ -lactamase-positive <i>Escherichia coli</i> among carbapenem non-susceptible Enterobacteriaceae in Taiwan during 2016 to 2018. <i>Scientific Reports</i> , 2021, 11, 2609.	3.3	16
15	Trends of recent hepatitis C virus infection among HIV-positive men who have sex with men in Taiwan, 2011-2018. <i>EClinicalMedicine</i> , 2020, 24, 100441.	7.1	15
16	Changing seroprevalence of hepatitis C virus infection among HIV-positive patients in Taiwan. <i>PLoS ONE</i> , 2018, 13, e0194149.	2.5	14
17	Impact of initiation of combination antiretroviral therapy according to the WHO recommendations on the survival of HIV-positive patients in Taiwan. <i>Journal of Microbiology, Immunology and Infection</i> , 2020, 53, 936-945.	3.1	14
18	Evolution of hepatitis A virus seroprevalence among HIV-positive adults in Taiwan. <i>PLoS ONE</i> , 2017, 12, e0186338.	2.5	13

#	ARTICLE	IF	CITATIONS
19	Efficacy and Safety of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide as Maintenance Treatment in HIV/HBV-Coinfected Patients. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2021, 86, 473-481.	2.1	13
20	Impact of antiretroviral therapy containing tenofovir disoproxil fumarate on the survival of patients with HBV and HIV coinfection. <i>Liver International</i> , 2019, 39, 1408-1417.	3.9	13
21	Effectiveness of COVID-19 vaccination among people living with HIV during a COVID-19 outbreak. <i>Journal of Microbiology, Immunology and Infection</i> , 2022, 55, 535-539.	3.1	13
22	Kidney dysfunction associated with tenofovir exposure in human immunodeficiency virus-1-infected Taiwanese patients. <i>Journal of Microbiology, Immunology and Infection</i> , 2017, 50, 595-603.	3.1	12
23	Incidence and impact of low-level viremia among people living with HIV who received protease inhibitor- or dolutegravir-based antiretroviral therapy. <i>International Journal of Infectious Diseases</i> , 2021, 105, 147-151.	3.3	12
24	A cross-sectional seroprevalence for COVID-19 among healthcare workers in a tertiary care hospital in Taiwan. <i>Journal of the Formosan Medical Association</i> , 2021, 120, 1459-1463.	1.7	12
25	Low-level viraemia and virologic failure among people living with HIV who received maintenance therapy with co-formulated bicitegravir, emtricitabine and tenofovir alafenamide versus dolutegravir-based regimens. <i>International Journal of Antimicrobial Agents</i> , 2022, 60, 106631.	2.5	12
26	Comparative in vitro activity of sitafloxacin against bacteremic isolates of carbapenem resistant <i>Acinetobacter baumannii</i> complex. <i>Journal of Microbiology, Immunology and Infection</i> , 2015, 48, 545-551.	3.1	11
27	Hepatitis B virus seroprevalence among HIV-infected patients receiving combination antiretroviral therapy three decades after universal neonatal hepatitis B immunization program in Taiwan. <i>Journal of Microbiology, Immunology and Infection</i> , 2021, 54, 228-237.	3.1	10
28	Serological responses to revaccination against HBV in HIV-positive patients born in the era of nationwide neonatal HBV vaccination. <i>Liver International</i> , 2018, 38, 1920-1929.	3.9	9
29	High rates of misidentification of uncommon <i>Candida</i> species causing bloodstream infections using conventional phenotypic methods. <i>Journal of the Formosan Medical Association</i> , 2021, 120, 1179-1187.	1.7	9
30	Serological survey in close contacts with a confirmed case of H7N9 influenza in Taiwan. <i>Journal of Infection</i> , 2013, 67, 494-495.	3.3	7
31	Fungal Diseases in Taiwan National Insurance Data and Estimation. <i>Journal of Fungi</i> (Basel), 2021, 7, 10784314. <sup>3.5</sup> <sup>7</sup>	3.5	7
32	Sexually-transmitted hepatitis C virus reinfections among people living with HIV in Taiwan: the emerging role of genotype 6. <i>Emerging Microbes and Infections</i> , 2022, 11, 1227-1235.	6.5	7
33	Metal nanoparticles and nanoparticle composites are effective against <i>Haemophilus influenzae</i> , <i>Streptococcus pneumoniae</i> , and multidrug-resistant bacteria. <i>Journal of Microbiology, Immunology and Infection</i> , 2022, 55, 708-715.	3.1	7
34	Hepatitis C microelimination among people living with HIV in Taiwan. <i>Emerging Microbes and Infections</i> , 2022, 11, 1664-1671.	6.5	6
35	Experience of the use of hydroxychloroquine on patients with COVID-19: A perspective on viral load and cytokine kinetics. <i>Journal of the Formosan Medical Association</i> , 2021, 120, 1269-1273.	1.7	4
36	Incidence of low-level viremia and its impact on virologic failure among people living with HIV-1 who switched to elvitegravir-based antiretroviral therapy. <i>Journal of Global Antimicrobial Resistance</i> , 2022, 29, 7-16.	2.2	3

#	ARTICLE	IF	CITATIONS
37	Risk of elevation of serum creatine kinase among HIV-positive individuals receiving dolutegravir-based combination antiretroviral therapy. <i>Medicine (United States)</i> , 2019, 98, e16235.	1.0	2
38	Dose-Related Aberrant Inhibition of Intracellular Perforin Expression by S1 Subunit of Spike Glycoprotein That Contains Receptor-Binding Domain from SARS-CoV-2. <i>Microorganisms</i> , 2021, 9, 1303.	3.6	2
39	Screening for Cryptococcal Antigenemia and Burden of Cryptococcosis at the Time of HIV Diagnosis: A Retrospective Multicenter Study. <i>Infectious Diseases and Therapy</i> , 2021, 10, 1363-1377.	4.0	1
40	Seroepidemiology of the human herpesvirus 8 infection among people living with HIV in Taiwan, 2014–2018. <i>Journal of Microbiology, Immunology and Infection</i> , 2021, 54, 934-943.	3.1	1